Drägerwerk AG & Co KGaA

Q324: Safety weakness not worrisome, for now

30/10/24 -"Drägerwerk’s Q3 24 numbers were exactly in line with the prelims. Sales were down, with declines across both segments. However, with a book-to-bill ratio of >1 across both segments, we ..."

PDF page sample
Pages
50
Language
English
Published on
30/10/24
Download
You may also be interested by these reports :
06/08/26
Qiagen’s Q2 results exceeded expectations and management’s guidance. Revenue growth was primarily driven by Sample Technologies and Genomics/NGS. ...
06/08/26
CZM’s Q3 results exceeded expectations, with top-line growth driven by strong performance in Microsurgery. Ophthalmology showed modest growth. The ...
06/08/26
FMC delivered better-than-expected Q2 26 results on revenue and adjusted EBIT, though the margin beat was heavily reimbursement-driven and ...
05/08/26
Fresenius delivered a strong Q2, with adjusted EBIT and core EPS coming in comfortably ahead of expectations and revenue broadly in line. The beat ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO